Cue Biopharma Inc (NAS:CUE)
$ 1.69 -0.17 (-9.09%) Market Cap: 101.75 Mil Enterprise Value: 93.22 Mil PE Ratio: 0 PB Ratio: 3.78 GF Score: 64/100

Cue Biopharma Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 09:00PM GMT
Release Date Price: $17.21 (-2.22%)
Albert Hwang;Morgan Stanley;Managing Director
Head of Biotechnology Investment Banking,

Good afternoon, everybody. Thank you for coming today for the Morgan Stanley Healthcare Conference. Today, this afternoon, I have with me Dan Passeri, the CEO of Cue. And why don't I pass it off to Dan to introduce the rest of the management team? The format here will be a 10-minute overview of the company followed by a Q&A led by me. (Operator Instructions) Dan?

Daniel R. Passeri
Cue Biopharma, Inc. - CEO & Director

Okay. Thanks, Albert. Good afternoon, everyone. I'm joined here by -- with my colleague, Anish Suri, who's President and Chief Scientific Officer of Cue Biopharma.

Just to remind everyone, Cue is a NASDAQ-listed company. Symbol is CUE. I also want to thank Morgan Stanley for giving us an opportunity to present.

I'm going to be advancing slides here at our facility, and I'll tell you which slides we're on. You can advance them off of your computers directly.

We're now moving to Slide 2.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot